BALDI , Federico

COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with the host immune system and the role of therapy still remains only partly understood. There are no data regarding the use of monoclonal antibodies and the combination of two antivirals in fighting viral replication and disease progression. We report the...

Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this...

Twenty-two immunocompromised patients with prolonged/relapsed COVID-19 received combination therapy with 2 antivirals (remdesivir + nirmatrelvir/ritonavir, n = 20; remdesivir + molnupiravir, n = 2) together with anti-spike monoclonal antibodies in 18. The response rate at day 14, day 30, and last follow-up was 75%, 73%, and 82%,...

Background The objective of this study was to compare the clinical outcomes of patients receiving a short course (SC) vs a prolonged course (PC) of antifungal therapy for uncomplicated Candida bloodstream infections (BSIs).Methods All episodes of uncomplicated Candida BSI from September 1, 2018, to August 31, 2020, were reviewed. We compared...